SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Burzynski Research Institute Inc – ‘10-Q’ for 5/31/12 – EX-101.INS

On:  Monday, 7/16/12, at 4:06pm ET   ·   For:  5/31/12   ·   Accession #:  1104659-12-49123   ·   File #:  0-23425

Previous ‘10-Q’:  ‘10-Q’ on 1/17/12 for 11/30/11   ·   Next:  ‘10-Q’ on 10/15/12 for 8/31/12   ·   Latest:  ‘10-Q’ on 1/14/19 for 11/30/18

  in   Show  &   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 7/16/12  Burzynski Research Institute Inc  10-Q        5/31/12   25:1.0M                                   Merrill Corp-MD/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    203K 
 2: EX-31.1     Certification per Sarbanes-Oxley Act (Section 302)  HTML     17K 
 3: EX-31.2     Certification per Sarbanes-Oxley Act (Section 302)  HTML     16K 
 4: EX-32.1     Certification per Sarbanes-Oxley Act (Section 906)  HTML     13K 
 5: EX-32.2     Certification per Sarbanes-Oxley Act (Section 906)  HTML     13K 
13: EXCEL       XBRL IDEA Workbook -- Financial Report (.xls)        XLS     72K 
19: R1          Document and Entity Information                     HTML     32K 
15: R2          Balance Sheets                                      HTML     64K 
18: R3          Balance Sheets (Parenthetical)                      HTML     27K 
20: R4          Statements of Operations                            HTML     49K 
22: R5          Statement of Stockholders' Deficit                  HTML     24K 
16: R6          Statements of Cash Flows                            HTML     50K 
17: R7          Basis of Presentation                               HTML     24K 
14: R8          Economic Dependency                                 HTML     26K 
12: R9          Stock Options                                       HTML     24K 
24: R10         Income Taxes                                        HTML     38K 
21: R11         Subsequent Events                                   HTML     14K 
25: XML         XBRL XML File -- Filing Summary                      XML     29K 
 6: EX-101.INS  XBRL Instance -- bzyr-20120531                       XML    115K 
 8: EX-101.CAL  XBRL Calculations -- bzyr-20120531_cal               XML     53K 
 9: EX-101.DEF  XBRL Definitions -- bzyr-20120531_def                XML    118K 
10: EX-101.LAB  XBRL Labels -- bzyr-20120531_lab                     XML    361K 
11: EX-101.PRE  XBRL Presentations -- bzyr-20120531_pre              XML    191K 
 7: EX-101.SCH  XBRL Schema -- bzyr-20120531                         XSD     37K 
23: ZIP         XBRL Zipped Folder -- 0001104659-12-049123-xbrl      Zip     31K 


EX-101.INS   —   XBRL Instance — bzyr-20120531


This exhibit is an XBRL XML File.


                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu XWand B0126 -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:bzyr="http://www.burzynskiresearch.com/20120531" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
<link:schemaRef xlink:type="simple" xlink:href="bzyr-20120531.xsd"/>
<xbrli:context id="I2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-02-28 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2012Q1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2011-03-01 </xbrli:startDate>
<xbrli:endDate> 2011-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-02-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q1_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="D2013Q1_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-03-01 </xbrli:startDate>
<xbrli:endDate> 2012-05-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q1_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q1_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2013Q1_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2012-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="I2012Q1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000724445 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2011-05-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="USD">
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Shares">
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USDPerShare">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<us-gaap:AssetsCurrent id="Tag3" decimals="0" contextRef="I2012" unitRef="USD"> 17297 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Tag5" decimals="0" contextRef="I2012" unitRef="USD"> 3419 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Tag7" decimals="0" contextRef="I2012" unitRef="USD"> 20716 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent id="Tag9" decimals="0" contextRef="I2012" unitRef="USD"> 12265 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Tag11" decimals="0" contextRef="I2012" unitRef="USD"> 49699 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:Liabilities id="Tag15" decimals="0" contextRef="I2012" unitRef="USD"> 61964 </us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies id="Tag18" xsi:nil="true" contextRef="I2012" unitRef="USD"/>
<us-gaap:CommonStockValue id="Tag19" decimals="0" contextRef="I2012" unitRef="USD"> 131449 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Tag21" decimals="0" contextRef="I2012" unitRef="USD"> 101428376 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Tag23" decimals="0" contextRef="I2012" unitRef="USD"> -101601073 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:LiabilitiesAndStockholdersEquity id="Tag27" decimals="0" contextRef="I2012" unitRef="USD"> 20716 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare id="Tag33" decimals="INF" contextRef="I2012" unitRef="USDPerShare"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Tag34" decimals="INF" contextRef="I2012" unitRef="Shares"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Tag35" decimals="INF" contextRef="I2012" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Tag36" decimals="INF" contextRef="I2012" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<dei:EntityRegistrantName id="Tag101" contextRef="D2013Q1"> BURZYNSKI RESEARCH INSTITUTE INC </dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Tag102" contextRef="D2013Q1"> 0000724445 </dei:EntityCentralIndexKey>
<dei:DocumentType id="Tag103" contextRef="D2013Q1"> 10-Q </dei:DocumentType>
<dei:DocumentPeriodEndDate id="Tag104" contextRef="D2013Q1"> 2012-05-31 </dei:DocumentPeriodEndDate>
<dei:AmendmentFlag id="Tag105" contextRef="D2013Q1"> false </dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate id="Tag106" contextRef="D2013Q1"> --02-28 </dei:CurrentFiscalYearEndDate>
<dei:EntityCurrentReportingStatus id="Tag109" contextRef="D2013Q1"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory id="Tag110" contextRef="D2013Q1"> Smaller Reporting Company </dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding id="Tag112" decimals="INF" contextRef="I2013Q1" unitRef="Shares"> 131448444 </dei:EntityCommonStockSharesOutstanding>
<dei:DocumentFiscalYearFocus id="Tag113" contextRef="D2013Q1"> 2013 </dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Tag114" contextRef="D2013Q1"> Q1 </dei:DocumentFiscalPeriodFocus>
<us-gaap:AssetsCurrent decimals="0" contextRef="I2013Q1" unitRef="USD"> 14949 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet decimals="0" contextRef="I2013Q1" unitRef="USD"> 3248 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets decimals="0" contextRef="I2013Q1" unitRef="USD"> 18197 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent decimals="0" contextRef="I2013Q1" unitRef="USD"> 55348 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent decimals="0" contextRef="I2013Q1" unitRef="USD"> 80554 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="I2013Q1" unitRef="USD"/>
<us-gaap:CommonStockValue decimals="0" contextRef="I2013Q1" unitRef="USD"> 131449 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock decimals="0" contextRef="I2013Q1" unitRef="USD"> 103031946 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit decimals="0" contextRef="I2013Q1" unitRef="USD"> -103281100 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:LiabilitiesAndStockholdersEquity decimals="0" contextRef="I2013Q1" unitRef="USD"> 18197 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:Liabilities decimals="0" contextRef="I2013Q1" unitRef="USD"> 135902 </us-gaap:Liabilities>
<us-gaap:CommonStockParOrStatedValuePerShare decimals="INF" contextRef="I2013Q1" unitRef="USDPerShare"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized decimals="INF" contextRef="I2013Q1" unitRef="Shares"> 200000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued decimals="INF" contextRef="I2013Q1" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding decimals="INF" contextRef="I2013Q1" unitRef="Shares"> 131448444 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2013Q1" unitRef="USD"> 14949 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2012" unitRef="USD"> 17297 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2013Q1" unitRef="USD"> -117705 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2012" unitRef="USD"> -41248 </us-gaap:StockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2013Q1" unitRef="USD"> 1538440 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2013Q1" unitRef="USD"> 141516 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2013Q1" unitRef="USD"> 171 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:OperatingExpenses decimals="0" contextRef="D2013Q1" unitRef="USD"> 1680127 </us-gaap:OperatingExpenses>
<us-gaap:OtherNonoperatingIncome decimals="0" contextRef="D2013Q1" unitRef="USD"> 100 </us-gaap:OtherNonoperatingIncome>
<us-gaap:ResearchAndDevelopmentExpense decimals="0" contextRef="D2012Q1" unitRef="USD"> 1434654 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense decimals="0" contextRef="D2012Q1" unitRef="USD"> 66076 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization decimals="0" contextRef="D2012Q1" unitRef="USD"> 177 </us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:OperatingExpenses decimals="0" contextRef="D2012Q1" unitRef="USD"> 1500907 </us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2013Q1" unitRef="USD"> -1680027 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2012Q1" unitRef="USD"> -1500907 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2013Q1" unitRef="USD"> -1680027 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2012Q1" unitRef="USD"> -1500907 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2013Q1" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2013Q1" unitRef="USDPerShare"> -0.01 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted decimals="2" contextRef="D2012Q1" unitRef="USDPerShare"> -0.01 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="0" contextRef="D2013Q1" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals="0" contextRef="D2012Q1" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="0" contextRef="D2013Q1" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals="0" contextRef="D2012Q1" unitRef="Shares"> 131448444 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding decimals="INF" contextRef="I2012_CommonStockMember" unitRef="Shares"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2012_CommonStockMember" unitRef="USD"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2012_AdditionalPaidInCapitalMember" unitRef="USD"> 101428376 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2012_RetainedEarningsMember" unitRef="USD"> -101601073 </us-gaap:StockholdersEquity>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed decimals="0" contextRef="D2013Q1_AdditionalPaidInCapitalMember" unitRef="USD"> 136558 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses decimals="0" contextRef="D2013Q1_AdditionalPaidInCapitalMember" unitRef="USD"> -1467012 </bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses>
<bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed decimals="0" contextRef="D2013Q1" unitRef="USD"> 136558 </bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed>
<bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses decimals="0" contextRef="D2013Q1" unitRef="USD"> -1467012 </bzyr:AdjustmentsToAdditionalPaidInCapitalClinicalTrialExpenses>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic decimals="0" contextRef="D2013Q1_RetainedEarningsMember" unitRef="USD"> -1680027 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:SharesOutstanding decimals="INF" contextRef="I2013Q1_CommonStockMember" unitRef="Shares"> 131448444 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2013Q1_CommonStockMember" unitRef="USD"> 131449 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2013Q1_AdditionalPaidInCapitalMember" unitRef="USD"> 103031946 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity decimals="0" contextRef="I2013Q1_RetainedEarningsMember" unitRef="USD"> -103281100 </us-gaap:StockholdersEquity>
<bzyr:ClinicalTrialExpensesPaid decimals="0" contextRef="D2013Q1" unitRef="USD"> 1467012 </bzyr:ClinicalTrialExpensesPaid>
<bzyr:ClinicalTrialExpensesPaid decimals="0" contextRef="D2012Q1" unitRef="USD"> 1373855 </bzyr:ClinicalTrialExpensesPaid>
<us-gaap:IncreaseDecreaseInAccountsPayable decimals="0" contextRef="D2013Q1" unitRef="USD"> 43083 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable decimals="0" contextRef="D2012Q1" unitRef="USD"> -12965 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals="0" contextRef="D2013Q1" unitRef="USD"> 30855 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals="0" contextRef="D2012Q1" unitRef="USD"> 32000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2013Q1" unitRef="USD"> -138906 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations decimals="0" contextRef="D2012Q1" unitRef="USD"> -107840 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:ProceedsFromContributedCapital decimals="0" contextRef="D2013Q1" unitRef="USD"> 136558 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:ProceedsFromContributedCapital decimals="0" contextRef="D2012Q1" unitRef="USD"> 106390 </us-gaap:ProceedsFromContributedCapital>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2013Q1" unitRef="USD"> 136558 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations decimals="0" contextRef="D2012Q1" unitRef="USD"> 106390 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2013Q1" unitRef="USD"> -2348 </us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:NetCashProvidedByUsedInContinuingOperations decimals="0" contextRef="D2012Q1" unitRef="USD"> -1450 </us-gaap:NetCashProvidedByUsedInContinuingOperations>
<us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2011" unitRef="USD"> 17476 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue decimals="0" contextRef="I2012Q1" unitRef="USD"> 16026 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:SubsequentEventsTextBlock contextRef="D2013Q1">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE E.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">                                              </font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">SUBSEQUENT EVENTS</font></i></b></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to 10% of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of 2,000,000 shares of the Company’s Common Stock, exercisable at $0.10 per share with a ten year exercise period, with 1,000,000 shares vesting upon execution of the agreement and the remaining 1,000,000 shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. Through the date of this report, none of the aforementioned warrants have been exercised.</font></p></td></tr></table>
</us-gaap:SubsequentEventsTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="D2013Q1">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE D.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">                                              </font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">INCOME TAXES</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company follows the provisions of FASB ASC 740-10, “Accounting for Uncertainty in Income Taxes”.  The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The federal income tax returns of the Company for 2010, 2009, and 2008 are subject to examination by the IRS, generally for three years after they are filed.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The actual provision for income tax for the three months ended May 31, 2012 and 2011, respectively, differ from the amounts computed by applying the U.S. federal income tax rate of 34% to the pretax loss as a result of the following:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="33%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">Three Months Ended May 31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2011</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Expected income tax benefit</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(571,209</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(510,308</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Effect of expenses deducted directly by Dr. Burzynski</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">571,209</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">510,308</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Nondeductible expenses and other adjustments</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(25,982</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">7,026</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Change in valuation allowance</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">25,982</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">(7,026</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">)</font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">State tax</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"></font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"></font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="62%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Income tax expense</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"></font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"></font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">At May 31, 2012, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $182,628.  The Company’s ability to utilize net operating loss carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income.  The Company has no historical earnings on which to base an expectation of future taxable income.  Accordingly, a valuation allowance for deferred tax assets has been provided.  At May 31, 2012, the Company had net operating loss carryforwards available to offset future taxable income in the amount of $392,415, which may be carried forward and will expire if not used between 2013 and 2033 in varying amounts.</font></p></td></tr></table>
</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2013Q1">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE C.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">                                              </font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">STOCK OPTIONS</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">At May 31, 2012, the Company had one stock-based employee compensation plan, which is described below.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company.  The options vested as follows:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.5in" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="64%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="30%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">Vesting Date</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">400,000 options</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">September 14, 1996</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">100,000 options</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">June 1, 1997</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 64.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="64%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">100,000 options</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">June 1, 1998</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The options are valid in perpetuity.  In addition, for a period of 10 years from the grant date, they increase in the same percentage of any new shares of stock issued; however, no shares were issued during such 10-year periods from the grant dates.  None of the options have been exercised as of May 31, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company accounts for stock-based compensation under the provisions of Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 718, “Compensation — Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee officers based on estimated fair values</font><font style="FONT-SIZE: 10pt" size="2"> </font><font style="FONT-SIZE: 10pt" size="2">as of the date of grant. Compensation expense is recognized on a straight-line basis over the requisite service period</font><font style="FONT-SIZE: 10pt" size="2">.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company did not grant any options and no options previously granted vested in any of the periods presented in these financial statements. Thus, there was no effect on net loss and earnings per share regarding the provisions of FASB ASC 718 in any of the periods presented.</font></p></td></tr></table>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D2013Q1">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE A.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">                                              </font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">BASIS OF PRESENTATION</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The financial statements of Burzynski Research Institute, Inc., a Delaware corporation (the “Company”), include expenses incurred directly by S.R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) within his medical practice, related to the conduct of U.S. Food and Drug Administration (“FDA”) approved clinical trials for Antineoplaston drugs used in the treatment of cancer.  These expenses have been reported as research and development costs and as additional paid-in capital.  Cash contributions received from Dr. Burzynski, which are used to fund general operating expenses, have also been reported as additional paid-in capital. Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements.  Dr. Burzynski is the President, Chairman of the Board and owner of 80.9% of the outstanding stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons,” which he has licensed to the Company.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company and Dr. Burzynski have entered into various agreements which provide the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once an Antineoplaston drug is approved for sale by the FDA.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.  The Company is currently conducting clinical trials on various Antineoplastons in accordance with FDA regulations. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of May 31, 2012 and February 29, 2012, results of operations for the three months ended May 31, 2012 and 2011, and cash flows for the three months ended May 31, 2012 and 2011.  All adjustments are of a normal recurring nature.  The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.  These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 29, 2012.</font></p></td></tr></table>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D2013Q1">
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">NOTE B.</font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1">                                              </font></i></b><b><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">ECONOMIC DEPENDENCY</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit.  Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice.  A portion of Dr. Burzynski’s patients are admitted and treated as part of the clinical trial programs, which are regulated by the FDA.  The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA.  These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">It is also the intention of the directors and management to seek additional capital through the sale of securities.  The proceeds from such sales will be used to fund the Company’s operating deficit until it achieves positive operating cash flow.  There can be no assurance that the Company will be able to raise such additional capital.</font></p></td></tr></table>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment decimals="0" contextRef="I2013Q1" unitRef="USD"> 19167 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment decimals="0" contextRef="I2012" unitRef="USD"> 18996 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
</xbrli:xbrl>
  Top
Filing Submission 0001104659-12-049123   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2019 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 20, 4:39:02.1pm ET